BACKGROUND: Omalizumab has been a valuable option for @entity1 with severe @entity56 , but there are only case reports regarding effectiveness of omalizumab in @entity1 with @entity5929 ( @entity5929 ). OBJECTIVE: To evaluate the clinical and functional effectiveness of omalizumab in @entity1 with @entity565 and @entity5929 in long-term follow-up. METHODS: The study was conducted as a retrospective chart review of @entity1 with @entity5929 who were treated with omalizumab injections between December 2008 and June 2014. Once treatment with omalizumab was started, data were collected at three time points: at baseline, after 1 year, and, in June 2014, at the last follow-up. RESULTS: Fourteen @entity1 with @entity5929 (seven @entity1 and seven @entity1 ; mean [   standard deviation (SD)] age, 44.21    13.01 years) were included. The treatment period was 31.5    3.99 months (mean    SD). The difference between the baseline and the last evaluation of the mean percentage of forced expiratory volume in 1 second (FEV1) was significant (p = 0.02). The mean @entity565 control test score was increased at all-time points compared with the basal score (p = 0.001). After omalizumab treatment was initiated, the @entity1 ' mean oral @entity228 dosage significantly decreased (p = 0.001). The baseline exacerbation rate was 2.7    1.5/y (mean    SD), and the hospitalization rate was 1.4/y, and both were zero at the last assessment (p = 0.001). Eleven of the @entity1 (78.6%) responded perfectly, and three (21.4%) partially responded to treatment. The @entity1 who had a total immunoglobulin E level of <1000 IU/mL seemed to be more responsive than those whose total immunoglobulin E level was >1000 IU/mL (p = 0.05). CONCLUSION: Omalizumab provided a clinically important reduction in exacerbations and @entity479 requirement, and improved @entity565 symptoms and pulmonary function parameters in @entity1 with @entity565 and @entity5929 who had previously shown an unsatisfactory response to Global Initiative for Asthma step 4 treatment.

Omalizumab in the treatment of XXXX : One center's experience with 14 cases.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity5929 :: ('MESH:D001229', 'Disease') :: ['ABPA', 'allergic bronchopulmonary aspergillosis'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic asthma'] @entity479 :: ('D013256', 'Chemical') :: ['steroid']
@entity5929 :: (MESH:D001229,Disease) :: ['allergic bronchopulmonary aspergillosis']
